StockNews.com Initiates Coverage on Oragenics (NYSE:OGEN)

Equities researchers at StockNews.com started coverage on shares of Oragenics (NYSE:OGEN) in a report released on Friday. The brokerage set a “sell” rating on the stock.

Oragenics Stock Performance

Shares of OGEN stock opened at $0.22 on Friday. Oragenics has a fifty-two week low of $0.21 and a fifty-two week high of $3.43. The firm has a market capitalization of $4.64 million, a PE ratio of -0.03 and a beta of 0.85. The stock’s 50-day simple moving average is $0.28 and its 200-day simple moving average is $0.33.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.